Proto Labs Inc: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Oct 31, 2017 and accepted by EDGAR at Oct 31, 2017, 14:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $38.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $109.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2017-07-01 to 2017-09-30 | $49.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2017-01-01 to 2017-09-30 | $141.0m | us-gaap:GrossProfit |
| Research and development | 3 months2017-07-01 to 2017-09-30 | $5.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $17.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | $19.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | $53.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $6.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $17.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | $13.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | $37.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | $0.49 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | $1.40 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | $0.50 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | $1.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 26,802,034 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 26,716,553 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $59.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $24.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2017-01-01 to 2017-09-30 | $4.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-09-30 | $119.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $234.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $477.6m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $35.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $47.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $429.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-17-017948. Last ingested by Listed: Nov 4, 2026, 18:20 ET. Listed shows no prices and gives no investment advice.